VP6: A candidate rotavirus vaccine

Journal of Infectious Diseases

Volumn 202, Issue SUPPL. 1, 2010, Pages

  Ward, Richard L ^a   McNeal, Monica M ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MALTOSE BINDING PROTEIN; PROTEIN VP6; ROTAVIRUS VACCINE;

ANIMAL EXPERIMENT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; IMMUNITY; IMMUNIZATION; LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS STRAIN;

ANIMALS; ANTIGENS, VIRAL; CAPSID PROTEINS; FECES; MICE; MODELS, ANIMAL; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VIRUS SHEDDING;

EID: 77955676002     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/653556     Document Type: Review

References (38)

1. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22.
2. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33.
3. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344: 564-572.
4. DeMol P, Zissis G, Butzler J-P, et al. Failure of live, attenuated oral rotavirus vaccine. Lancet 1986; 2:108.
5. Georges-Courbot MC, Monges J, Siopathis MR, et al. Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. Res Virol 1991; 142:405-411.
6. Santosham M, Letson GW, Wolff M, et al. A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population. J Infect Dis 1991; 163:483-487.
7. Hanlon P, Hanlon L, Marsh V, et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1987; 1: 1342-1345.
8. Flores J, Kapikian AZ. Vaccines against rotavirus. In Woodrow GC, Levine MM, eds. New generation vaccines. New York: Marcel Dekker, 1990:765-788.
9. McNeal MM, Rae MN, Bean JA, Ward RL. Antibody-dependent and -independent protection following intranasal immunization of mice with rotavirus particles. J Virol 1999; 73:7565-7573.
10. Yuan L, Ward LA, Rosen BI, To TL, Saif LJ. Systemic and intestinal antibody-secreting cell responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease. J Virol 1996; 70:3075-3083.
11. O'Neal CM, Crawford SE, Estes MK, et al. Rotavirus virus-like particles administered mucosally induce protective immunity. J Virol 1997; 71: 8707-8717.
12. Estes MK, Kapikian AZ. Rotaviruses. In: Knipe DM, Howley PM, Griffin DE, et al., eds. Fields virology, fifth edition. Philadelphia: Lippincott, Williams & Wilkins, 2007:1917-1974.
13. Yoder JD, Dormitzer PR. Alternative intermolecular contacts underlie the rotavirus VP5* two- to three-fold rearrangement. EMBO J 2006; 25:1559-1568.
14. Tang B, Gilbert JM, Matsui SM, et al. Comparison of the rotavirus gene 6 from different species by sequence analysis and localization of subgroup-specific epitopes using site-directed mutagenesis. Virology 1997; 237:89-96.
15. Greenberg H, McAuliffe V, Valdesuso J, et al. Serological analysis of the subgroup protein of rotavirus using monoclonal antibodies. Infect Immun 1983; 39:91-99.
16. Svensson l, Sheshberadaran H, Vene S, et al. Serum antibody responses to individual viral polypeptides in human rotavirus infections. J Gen Virol 1987; 68:643-651.
17. Ward R L, McNeal MM, Sheridan JF. Development of an adult mouse model for studies on protection against rotavirus. J Virol 1990; 64: 5070-5075.
18. McNeal MM, Rae MN, Conner ME, Ward RL. Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21. Virology 1998; 243:158-166.
19. Choi AH-C, Basu M, McNeal MM, et al. Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein. J Virol 1999; 73: 7574-7581.
20. Choi AH, McNeal MM, Basu M, et al. Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses. Vaccine 2002; 20:3310-3321.
21. McNeal MM, Basu M, Bean JA, et al. Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge. Vaccine 2007; 25:6224-6231.
22. Choi AH-C, Basu M, McNeal MM, et al. Functional mapping of protective domains and epitopes in the rotavirus VP6 protein. J Virol 2000; 74:11574-11580.
23. Franco MA, Greenberg HB. Role of B cells and cytotoxic T lymphocytes in clearance of and immunity to rotavirus infection in mice. J Virol 1995; 69:7800-7806.
24. McNeal MM, Barone KS, Rae MN, Ward RL. Effector functions of antibody and CD8+ cells in resolution of rotavirus infection and protection against reinfection in mice. Virology 1995; 214:387-397.
25. Feng N, et al. Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6-specific IgA mAb. J Clin Invest 2002; 109:1203-1213.
26. Schwartz-Cornil I, Benureau Y, Greenberg H, Hendrickson BA, Cohen J. Heterologous protection induced by the inner capsid proteins of rotavirus requires transcytosis of mucosal immunoglobulins. J Virol 2002; 76:8110-8117.
27. VanCott JL, Prada AE, McNeal MM, et al. Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with non-living VP6/LT(R192G) or orally with live RRV rotavirus vaccine candidates. J Virol 2006; 80:4949-4961.
28. Garaicoechea L, Olichon A, Marcoppido G, et al. Llama-derived singlechain antibody fragments directed to rotavirus VP6 protein possess broad neutralizing activity in vitro and confer protection against diarrhea in mice. J Virol 2008; 82:9753-9764.
29. McNeal MM, VanCott JL, Choi AH, et al. CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G). J Virol 2002; 76:560-568.
30. Banos DM, Lopez S, Arias CF, Esquivel FR. Identification of a T-helper cell epitope on the rotavirus VP6 protein. J Virol 1997; 71:419-426.
31. McNeal MM, Basu M, Bean JA, Clements JD, Choi AH, Ward RL. Identification of an immunodominant CD4+ T cell epitope in the VP6 protein of rotavirus following intranasal immunization of BALB/cmice. Virology 2007; 363:410-418.
32. Bass DM. Interferon gamma and interleukin 1, but not interferon alfa, inhibit rotavirus entry into human intestinal cell lines. Gastroenterology 1997; 113:81-89.
33. McNeal MM, Stone SC, Basu M, Clements JD, Choi AH, Ward RL. IFN-gamma is the only anti-rotavirus cytokine found after in vitro stimulation of memory CD4+ T cells from mice immunized with a chimeric VP6 protein. Viral Immunol 2007; 20:571-584.
34. Smiley KL, McNeal MM, Basu M, Choi AH, Clements JD, Ward RL. Association of IFN-g and IL-17 production in intestinal CD4+ T cells with protection against rotavirus shedding in mice intranasally immunized with VP6 and the adjuvant LT(R192G). J Virol 2007; 81: 3740-3748.
35. Ward RL. Rotavirus vaccines: how they work or don't work. Expert Rev Mol Med 2008; 10:5e.
36. Choi AH, McNeal MM, Flint JA, et al. The level of protection against shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant. Vaccine 2002; 20:1733-1740.
37. Blutt SE, Warfield KL, O'Neal CM, Estes MK, Conner ME. Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs). Vaccine 2006; 24:1170-1179.
38. To TL, Ward LA, Yuan L, Saif LJ. Serum and intestinal isotype antibody responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease. J Gen Virol 1998; 79:2661-2672.